What is Nektar Therapeutics?
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.27B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 68,464 shares $399k | 0 |